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sion-free survival (PFS), on the cohort of 2000 patients with Her2 Ne mBC negative
and a subanalysis of the populations of patients with triple negative of patients
with Her2 Neu Negative, taking into account direct medical costs and social costs
due to premature death, in a horizon of 5 years (discount rate 5%). RESULTS: The
40.35% of patients survived after 12 months using bevacizumab paclitaxel, while
only 35.20% did so with only administered paclitaxel. 59.6% of these patients were
PFS with combination therapy, while 37.71% did with monotherapy. Combined
therapy provides more effectiveness than monotherapy in terms of overall sur-
vival, progression-free survival (PFS) and therapeutic response. The incremental
cost of bevacizumab  paclitaxel is $9,639 USD obeying the PFS difference in time
between the two cohorts, and higher consumption on the combination versus
monotherapy. For triple negative subpopulation, the ICER is $2295 USD while for
the sub-population of HER 2 is $1854 USD. The ICER is compared against a threshold
of 3 times GDP per capita in Mexico. The ICER is lower than the threshold, so it is
cost-effective CONCLUSIONS: The combination of bevacizumab  paclitaxel, for
all cases studied, represents a better alternative cost effective versus paclitaxel
monotherapy.
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OBJECTIVES: : One-year adjuvant trastuzumab therapy increases disease-free and
overall survival in the adjuvant treatment of early HER2-positive breast cancer.
This study aims to assess the long-term cost-effectiveness of adjuvant trastu-
zumab treatment in Colombia METHODS: A Markov health-state transition model
was constructed to simulate the natural development of breast cancer in women
with HER2/neu-positive after 12 months of after trastuzumab adjuvant chemother-
apy over a lifetime perspective with annual transition cycles. The model incorpo-
rated five broad health states (disease-free, local recurrence [LCR], distant recur-
rence [DCR], cardiac failure, death). Baseline event rates and 3-year relative risk
(RR 0.75) were derived from the HERA trial. Costs and utility weights were from
the literature and were discounted by 3% annually RESULTS: On the basis of HERA
data, the model results showed that the utilization of adjuvant trastuzumab treat-
ment in early breast cancer can prolong 8.23 quality-adjusted life-years, compared
with 7, 78 quality-adjusted life-years in the standard chemotherapy group. The
incremental cost-effectiveness ratio was US$134,581. Results are moderately sen-
sitive to variation of relative risk, cost and number of cycles of trastuzumab and
less sensitive to breast cancer survival rates and variations in cardiac toxicity
CONCLUSIONS: The results suggest that the 1-year adjuvant trastuzumab treat-
ment is not cost-effective in Colombia. Both clinical and economic benefits were
not superior for the 1-year adjuvant trastuzumab treatment group compared with
the standard adjuvant chemotherapy group
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OBJECTIVES: To investigate the cost-effectiveness of the addition of trastuzumab
in a docetaxel monotherapy for women with HER2 metastatic breast cancer
(MBC) in the Greek healthcare setting.METHODS:A 3-state model was constructed
to simulate progression of the disease and overall quality adjusted survival for
patients receiving trastuzumab and docetaxel (TD) or docetaxel alone (D). The
model ran on 1-month cycles and simulated the progress of patients over a total
period of 12 years. Data on effectiveness were derived from a randomized con-
trolled trial comparing the outcomes of six cycles of docetaxel 100 mg/m2 every 3
weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg
weekly until disease progression in women with an average age of 53 years, and an
average body surface area of 1.7148m2. Costs were estimated from a third-party
payer perspective (2011 Euros), discounted at 3%/annum. RESULTS: Patients in the
TD arm had a mean incremental gain of 0.729 years (95% CI: 0.10, 1.36) in overall
survival and 0.449 (95% CI: 0.14 0.76) QALYs in quality-adjusted survival than those
in the D arm (1.992 vs. 1.542). Taking into account the average incremental cost of
30,474.62€ (95% CI: 23,592.04, 38,195.93) in the TD arm, the analysis reveals that
the Incremental Cost Effectiveness Ratios (ICERs) are estimated at 41,811.13€ and
67,824.92 for every life year or QALY, respectively, gained with trastuzumab. The
probabilistic sensitivity analysis showed that the ICERs produced by TD were
favourable at 17.1% of the Monte Carlo simulations at the 50,000€ and 35.7% at the
60,000€ threshold. CONCLUSIONS: The addition of trastuzumab to a first line treat-
ment of HER2 MBC with docetaxel represents an intervention with a high prob-
ability of being cost-effective from a third party-payer perspective
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OBJECTIVES: This study was performed to evaluate the cost-effectiveness of three
kinds of combination therapies including class II anti-cancer drugs in patients with
advanced or metastatic gastric cancer. METHODS: A Markov model was simulated
to assess the clinical and economic impact over 5 years from societal perspective.
Life Years Gained(LYG) were measured as a clinical outcome. In the model,
Docetaxelcisplatin5-FU(DCF), S-1cisplatin(SP), Capecitabinecisplatin(XP)
were selected as 1st line chemotherapies. When the disease progressed in the
second line therapy, Leucovorin 5-FU Irinotecan (FOLFIRI), it was assumed that
best supportive care was performed. Transition probabilities and mortality were
calculated by using adjusted parameter of “time to progression(TTP) or progression
free survival(PFS), overall survival(OS)”, which were obtained by indirect compar-
ison (control group: 5-FU  Cisplatin). Both direct medical costs and direct non-
medical costs were calculated. Costs and outcomes were discounted at an annual
rate of 5% and sensitivity analysis was performed to evaluate uncertainty in the
results. RESULTS: SP was dominated by XP because the total LYG per patient was
higher and cost was lower for XP compared with SP. When DCF was compared with
XP, incremental LYG was 0.045. However, incremental cost of DCF was also
10,719,975 KRW. Incremental cost-effectiveness ratio for DCF compared to XP was
calculated over 200 million per LYG. The results of the sensitivity analysis showed
no significant difference. CONCLUSIONS: Although a threshold of ICER is not fixed
in Korea, GDP per capita is usually used for reference. In that case, it is considered
that XP is cost-effective compared with DCF. Therefore, XP is the more cost-effec-
tive than DCF and SP. Further research should be carried out about cost-utility by
using utility weight according to the state of gastric cancer.
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OBJECTIVES: The incidence of cervical cancer in Spain is about 10/100,000 women
per year, one of the lowest in Europe. Screening programs and the population
vaccination against HPV are the two health care interventions aiming to reduce
cancer development.The objective of this study is to analyse the efficiency of the
population vaccination program in Spanish girls aged 11-14. METHODS: A simula-
tion discrete event model with a horizon of 20 years, under the perspective of the
National Health System, applied to the context of a high level of coverage Spanish
region (La Rioja) was developed. The cytological results of the population screening
program (14,760 women) and a review of literature on Spanish papers as well as
official statistics were used in the model. Finally, the model took also into account
the impact of some progression co-factors and the decrease on the immunity along
time. RESULTS: According to the model outputs, from the 2725 girls of the first
vaccination camping, 38.2% will not get infected by the HPV, 56.1% will clear the
virus in a spontaneous way, 3.8% will either not progress or do not confirm the
diagnoses, and, consequently, 1.9% would confirm a cervical lesion (29 LSIL and 23
HSIL), without considering the vaccination effect.A population vaccination pro-
gram (that reached a 97.5% coverage) vs no vaccination at all will have an Incre-
mental Cost Effectiveness Ratio of 43,657.8 euros per avoided pre-cancer cervical
lesion. CONCLUSIONS: Although some primary preventative measures are conve-
nient from a public health perspective, their final health and economic outcomes
should be analysed. According to the results of this study, targeting only some risk
populations should be considered as a way of increasing the low efficiency of the
general population vaccination program.
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OBJECTIVES: To analyze cost-effectiveness of a human papillomavirus (HPV) vac-
cination of boys at age 12 against oropharyngeal carcinoma and anogenital warts.
METHODS:We developed Markov decision model for a population of boys of age 12.
We assessed the following outcomes: costs, gains in quality adjusted life years
(QALYs), incremental cost-effectiveness ratio (ICER) for two options: vaccination
with quadrivalent vaccine and no vaccination, and for the two currently-available
vaccination choices: one with quadrivalent vaccine and one with bivalent vaccine.
We employed Monte Carlo microsimulation in the analysis of results. RESULTS:
Comparison of HPV vaccination of boys at age 12 vs. no vaccination resulted in ICER
of 109,384 GBP per QALY. The outcome was sensitive to the vaccination costs, the
probability of developing oropharyngeal carcinoma and anogenital warts, and pro-
portion of oropharyngeal carcinoma attributable to infection with types HPV-16
and HPV-18. When comparing quadrivalent and bivalent vaccines, resulting ICER
was 5,205 GPB per QALY. CONCLUSIONS:Our results indicate that HPV vaccination
of boys with quadrivalent vaccine is at present deemed not cost-effective, i.e., ICER
exceeds willingness-to-pay threshold of 30,000 GBP per QALY. Comparison of
quadrivalent and bivalent vaccines revealed that the additional benefits of protec-
tion against anogenital warts would favour quadrivalent vaccine as the vaccination
choice. An increase in incidence of HPV-positive oropharyngeal carcinoma and
anogenital warts, and reduction of vaccination costs could substantially reduce
ICER. Results of our study have potential healthcare policy implications for HPV
national immunisation programs in the UK and other jurisdictions of developed
countries.
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OBJECTIVES: To assess cost-effectiveness of rituximab (RTX) 1st line maintenance
treatment compared to observation (O) in patients with follicular lymphoma (FL)
from the Polish public payer perspective. METHODS: Efficacy and safety of ritux-
imab 1st line maintenance therapy was assessed based on the results of systematic
review and the PRIMA clinical trial. Direct medical costs were assessed based on
the data regarding clinical practice of FL treatment and medical resources use
gathered in 5 oncology centers. The following costs were calculated and included:
drugs, drug administration, treatment-related adverse events, lymphoma relapse
treatment, patient health monitoring. A life-time horizon (25 years) and public
payer perspective were assumed. Costs were discounted at 5% and effects at 3.5%.
A four health state Markov model (progression-free 1st line, progression-free sub-
sequent line, progression and death) was used. Sensitivity analysis was performed
testing the influence of various critical parameters such as utilities values, differ-
ent costs categories, length of time horizon and patient’s body surface. RESULTS:
Introduction of 1st line maintenance therapy with RTX resulted in gain of 1.4 life
years and 1.3 quality adjusted life years compared to observation. The total incre-
mental costs were 60,707 PLN (1 EURO3.96 PLN) which corresponded to an incre-
mental cost-effectiveness ratio (ICER) of 43,348 PLN and an incremental cost-utility
ratio (ICUR) of 47,357 PLN. Both values were below 110 000 PLN cost-effectiveness
threshold assumed by the Polish public payer. The results were sensitive to dis-
count rates, utilities values applied to the specific health states, length of time
horizon. None of the tested scenarios resulted in values of ICUR and ICER exceeding
the 110,000PLN threshold, providing evidence that rituximab treatment is cost-
effective from public payer perspective. CONCLUSIONS: Rituximab in 1st line
maintenance treatment of FL is an effective, safe and cost -effective therapeutic
option.
PCN87
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OBJECTIVES: To estimate the cost-effectiveness of cetuximab plus best supportive
care (BSC) or cetuximab plus chemotherapy in patients with EGFR-expressing
KRAS wild-type metastatic colorectal cancer who have failed at least two previous
chemotherapeutic regimens in the metastatic setting from the UK NHS
perspective. METHODS: A Markov model was developed to inform the cost-effec-
tiveness (CE) of cetuximab plus BSC and cetuximab plus chemotherapy both versus
BSC, and additionally the CE of cetuximab plus BSC and cetuximab plus chemo-
therapy both versus panitumumab plus BSC. Progression-free survival and overall
survival data were collected from the following clinical trials: Karapetis et al. 2008,
De Roock et al. 2007 and 2010, and Amado et al. 2008. These three clinical studies
were relevant to perform indirect treatment comparisons. RESULTS: In the base-
case analysis, treatments with cetuximab resulted in additional QALY as follows:
cetuximab plus BSC versus BSC (0.303), cetuximab plus chemotherapy versus BSC
(0.668), cetuximab plus BSC versus panitumumab plus BSC (0.193), and cetuximab
plus chemotherapy versus panitumumab plus BSC (0.616). The base-case incre-
mental cost effectiveness ratios (ICER) for cetuximab plus BSC and cetuximab plus
chemotherapy, both compared to BSC are in the region of £50,000 per QALY. Com-
pared to panitumumab plus BSC, the ICERs are below the NICE’s £30,000 willing-
ness-to-pay threshold. CONCLUSIONS:Weighting the QALYs gained with the NICE
supplementary advice, suggests that cetuximab plus BSC or cetuximab plus che-
motherapy is potentially a cost-effective use of NHS resources in this setting.
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OBJECTIVES: To assess the cost-effectiveness in France of current G-CSF strategies
as PP (from first cycle and before an FN event) and SP (after an FN event) for NHL
patients receiving cytotoxic chemotherapy. METHODS: A Markov model was de-
veloped to calculate cost per FN events avoided, life-year saved (LYS), and quality
adjusted life year (QALY); results were expressed as incremental cost-effectiveness
ratios (ICERs). ICERs for 9 prophylaxis strategies were evaluated for three NHL
chemotherapies (CHOP, CHOP-R and ACVBP): PP or SP with pegfilgrastim (Neu-
lasta®), 6-day filgrastim (Neupogen®), 11-day filgrastim, 6-day lenograstim; and no
prophylaxis. All strategies were compared to no prophylaxis. FN-related outcomes
including FN-hospitalizations, FN-mortality and RDI were assessed using epidemi-
ologic data, utility and chemotherapy-related FN-risk (21% for CHOP-21, 19% for
RCHOP-21, 52% for ACVBP). Direct healthcare costs (G-CSF, administration, and
FN-related events) were calculated from French Health insurance perspective.
Costs and outcomes were discounted (4%/year). Based on international guidelines,
PP should be given to high-risk patients (FN risk320%). RESULTS: In the high che-
motherapy FN-risk population, pegfilgrastim was the most cost-effective G-CSF
compared to SP-pegfilgratim. For instance, in patients undergoing ACVBP chemo-
therapy, ICERs with PP-pegfilgrastim were €2,019 per FN avoided, €10,194 per QALY
gained and €8,632 per LYS versus SP-pegfilgrastim. In RCHOP-21 and without con-
sidering patient risk factors, if SP was considered instead of no prophylaxis, peg-
filgrastim was the dominant G-CSF with ICERs of €2,112 per FN avoided, €14,703 per
QALY gained and €11,940 per LYS versus no prophylaxis. CONCLUSIONS: With
French settings, pegfilgrastim is the most cost-effective PP-G-CSF in high chemo-
therapy FN-risk patients versus SP-pegfilgrastim. After an FN event, pegfilgrastim
is the most cost-effective SP-G-CSF versus no prophylaxis.
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OBJECTIVES: To assess the public health impact of the quadrivalent (6,11,16,18)
HPV vaccination program for São Paulo, Brazil.METHODS:A published mathemat-
ical model of the transmission dynamics of HPV infection and disease was adapted
for São Paulo, Brazil. The model captured direct protective effects of vaccination
and indirect effects (herd immunity). Model inputs were used from Brazil or the
Latin/America region when available; otherwise, the default values in the original
model were used. Maintaining current cervical cancer screening practices in Brazil,
we evaluated two strategies: routine vaccination of females by age 12 (S1), and S1
combined with a temporary (5 years) female catch-up program for age 12–24 years
(S2). The vaccine coverage rates were 85% for the routine and 95% by age 26 years
for the catch-up vaccination programs. RESULTS: Comparing S1 to no vaccination,
we estimated the cumulative percent (absolute cases) reduction in HPV 6/11/16/18-
related incident genital warts-female, genital warts-male, cervical intraepithelial
neoplasia (CIN) grade 1, CIN 2/3, cervical cancer cases, and cervical cancer deaths
would be 78% (2,488,240), 67% (2,166,770), 68% (360,235), 65% (1,154,566), 47%
(135,810), and 44% (39,147), respectively, over 100 years. Compared to S1, S2 pro-
vided additional cumulative percent (absolute cases) reduction of 9% (273,866), 11%
(357,728), 7% (39,455), 7% (131,861), 7% (19,620), and 7% (6,009) in HPV 6/11/16/18-
related incident genital warts-female, genital warts-male, CIN 1, CIN 2/3, cervical
cancer cases, cervical cancer deaths. CONCLUSIONS: A prophylactic quadrivalent
HPV vaccination program for females in Sao Paulo, Brazil can substantially reduce
the incidence of cervical cancer, CIN, and genital warts. Female catch up vaccina-
tion may provide greater reductions in HPV-related diseases.
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OBJECTIVES: Evaluate the cost-effectiveness analysis of erlotinib compared with
docetaxel and pemetrexed in the second-line treatment of advanced non-small-
cell-lung cancer (NSCLC) from a societal perspective in a Russian setting.
METHODS: A Markov state transition model, based on two randomized phase III
studies of erlotinib versus pemetrexed (HORTC) and pemetrexed versus docetaxel
(Nasse H. et al 2005), was used to estimate total direct costs and quality-adjusted
life years (QALYs). Data about cost of medical services and drugs are received from
the price-list of out-patient medical aid in clinic MMA of I.M.Sechenov 01.02.2011,
site minzdravsoc.ru//medicine and other accessible electronic resources. Costs,
effectivenesses, utilities were discounted at 3%. Sensitivity analysis for key param-
eters in the model was conducted. RESULTS: Erlotinib was associated with a re-
duction in total costs (1 179 452 roubles versus 1 260 607 roubles and 1 769 367
roubles) and improved outcomes (total QALYs of 0.299 versus 0.248 and 0.271) in
comparison with docetaxel and pemetrexed, respectively. Sensitivity analysis
showed that major factors influencing cost-effectiveness and cost-utility ratios are
survival gain, price of drugs, discount rates. CONCLUSIONS: In summary erlotinib
is more cost-effective in comparison with docetaxel and pemetrexed for second-
line treatment of advanced NSCLC due to lower adverse event and drug adminis-
tration costs.
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REGIMES WITH BEVACIZUMAB OR CETUXIMAB AS THE FIRST LINE
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OBJECTIVES: This study is devoted on a comparative pharmacoeconomic analysis
regimes XELOX  BV (bevacizumab) versus XELOX  CET (cetuximab) treatment
(q3w); FOLFOX4  BV and FOLFOX4  CET (q2w) in the treatment of mCRC. The
efficacy and safety of combined treatment regimens based on the data of interna-
tional clinical trials. METHODS: Medical services were taken from the standards of
medical care for patients with ÑRC and their costs were based on the price-list of
Cancer Research Center. The cost analysis of anticancer and related drugs were
based on the information about limit selling/import prices of vital and essential
drugs. The main characteristics for Markov’s model were: the Markov states (with-
out progression, progression, death); a Markov’s cycle (1 month); the time horizon
(5 years). RESULTS: The cost of diagnosis was 16757 rubles, the medical services –
222802 rubles. The mCRC therapy as a first line by XELOX in combination with BV
was 1029694 rubles or with CET–1899867 ruble; FOLFOX4 in combination with BV–
1109402 rubles or with CET–2026917 rubles. The highest CER was for mode
XELOXCET-263870 rubles. The Markov’s model shows that the COST/QALY and
COST/LYG will above with each year, but in comparing groups with BV or CET
therapy in the next 5 years, it was shown a tendency of the increase in cost per
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